Sakar Healthcare Q2 FY27 Revenue up 53% to ₹8,741.61 Lakhs, PAT up 149%
Sakar Healthcare reported Q2 FY27 consolidated revenue of ₹8,741.61 lakhs, up 53% YoY. EBITDA grew 114% to ₹2,434.53 lakhs and PAT surged 149% to ₹1,130.69 lakhs. For H1 FY27, revenue was ₹11,029.66 lakhs, up 60% YoY, with PAT up 134% to ₹2,159.18 lakhs.
The substantial percentage increases in key financial metrics like revenue, EBITDA, and PAT are material and are likely to positively impact investor sentiment and the company's stock performance.
The company reported significant year-on-year growth in revenue, EBITDA, and Profit After Tax, indicating strong financial performance.
Sakar Healthcare Limited announced strong unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a significant year-on-year growth in revenue from operations, which increased by 53% to ₹8,741.61 lakhs for the second quarter (Q2 FY27) compared to ₹5,756.04 lakhs in the previous year.
For the half-year ended September 30, 2026 (H1 FY27), revenue from operations grew by 60% to ₹11,029.66 lakhs compared to ₹11,029.66 lakhs in H1 FY26. Gross Profit for Q2 FY27 rose by 53% YoY to ₹4,168.05 lakhs, and for H1 FY27, it increased by 57% YoY to ₹8,007.08 lakhs.
EBITDA saw a substantial jump of 114% YoY in Q2 FY27, reaching ₹2,434.53 lakhs, with an EBITDA margin of 28%. For H1 FY27, EBITDA grew by 90% YoY to ₹4,559.42 lakhs, maintaining a 28% margin. Profit After Tax (PAT) for Q2 FY27 surged by 149% YoY to ₹1,130.69 lakhs, with a PAT margin of 13%. H1 FY27 PAT increased by 134% YoY to ₹2,159.18 lakhs, also at a 13% margin.
Mr. Sanjay Shah, Managing Director, commented that Q2 FY27 was a quarter of meaningful progress for their oncology business, with encouraging developments across regulatory approvals, technology transfers, and global market access. He highlighted the commencement of commercial supplies from their EU GMP-approved, API-integrated oncology facility as a key milestone. Looking ahead, the company remains optimistic about its expanding oncology portfolio, growing pipeline, and international partnerships, expecting to drive export growth and operating efficiencies for sustainable, long-term growth.
What to do with a filing like this
Sakar Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sakar Healthcare Limited. Read the original for the full detail.